These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16184030)

  • 1. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.
    Thompson MA; Kessler HA; Eron JJ; Jacobson JM; Adda N; Shen G; Zong J; Harris J; Moxham C; Rousseau FS;
    AIDS; 2005 Oct; 19(15):1607-15. PubMed ID: 16184030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.
    Murphy RL; Kivel NM; Zala C; Ochoa C; Tharnish P; Mathew J; Pascual ML; Schinazi RF
    Antivir Ther; 2010; 15(2):185-92. PubMed ID: 20386073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection.
    Margolis DM; Mukherjee AL; Fletcher CV; Hogg E; Ogata-Arakaki D; Petersen T; Rusin D; Martinez A; Mellors JW
    AIDS; 2007 Oct; 21(15):2025-32. PubMed ID: 17885292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
    Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR;
    Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
    Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
    Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
    Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
    Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
    AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
    Gruzdev B; Rakhmanova A; Doubovskaya E; Yakovlev A; Peeters M; Rinehart A; de Dier K; Baede-Van Dijk P; Parys W; van 't Klooster G
    AIDS; 2003 Nov; 17(17):2487-94. PubMed ID: 14600520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
    AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.
    Ruane PJ; Richmond GJ; DeJesus E; Hill-Zabala CE; Danehower SC; Liao Q; Johnson J; Shaefer MS;
    Pharmacotherapy; 2004 Mar; 24(3):307-12. PubMed ID: 15040643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
    Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G
    AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.
    Mewshaw JP; Myrick FT; Wakefield DA; Hooper BJ; Harris JL; McCreedy B; Borroto-Esoda K
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):11-20. PubMed ID: 11782585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
    Schürmann D; Rudd DJ; Zhang S; De Lepeleire I; Robberechts M; Friedman E; Keicher C; Hüser A; Hofmann J; Grobler JA; Stoch SA; Iwamoto M; Matthews RP
    Lancet HIV; 2020 Mar; 7(3):e164-e172. PubMed ID: 31911147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
    Lalezari J; Thompson M; Kumar P; Piliero P; Davey R; Patterson K; Shachoy-Clark A; Adkison K; Demarest J; Lou Y; Berrey M; Piscitelli S
    AIDS; 2005 Sep; 19(14):1443-8. PubMed ID: 16135896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.